HopeStage
Back to all studies
WithdrawnNCT01543139

Cytidine- and Creatine-Containing Drug in Treating Depression in bipolarity

Medication studyAges 19–65South Korea
The study in practice

Understand this study

Who could participate?

Listed age limits: 19 years to 65 years.

Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: December 1, 2015
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Ewha Womans University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
South Korea
Age range
From 19 Years to 65 Years
Official registry ID
NCT01543139
Official title
Show the full official title

A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-Containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression

Recruitment & locations

Withdrawn

Seoul

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Ewha Womans University, a university.

Does this study involve medication?

Yes. The study involves medication, including Valproate+Cytidine-+Creatine-, Valproate+Cytidine- and valproate.

Who can participate?

Listed age limits: 19 years to 65 years.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies